Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service t...
Grail shares plunged over 45% after NHS revealed its Galleri multi-cancer blood test missed the trial's primary endpoint.
Why it mattersNHS Galleri trial failure should prompt investors and payers to reassess valuation and reimbursement assumptions.